Literature DB >> 9258425

Serum and mucosal antibody responses and protection in pigs vaccinated against Mycoplasma hyopneumoniae with vaccines containing a denatured membrane antigen pool and adjuvant.

S P Djordjevic1, G J Eamens, L F Romalis, P J Nicholls, V Taylor, J Chin.   

Abstract

OBJECTIVE: To investigate the protective efficacy of a pool of denatured membrane protein antigens of Mycoplasma hyopneumoniae (J strain) in the molecular size range 70 to 85 kDa (F3 antigen) in combination with adjuvants for pigs challenged with M hyopneumoniae.
DESIGN: A vaccine efficacy experiment with assessment of serum and respiratory tract antibody responses. PROCEDURE: F3 antigens were emulsified with five different adjuvants. To groups of three pigs per vaccine, four vaccines were given by intramuscular injection, and two vaccines, including one of those given intramuscularly, were given by intraperitoneal injection.
RESULTS: Compared to six unvaccinated pigs, animals vaccinated with F3 antigen displayed significantly reduced pneumonia (54% reduction in mean lung score) following experimental challenge. Analysis of post-vaccination, pre-challenge IgG and IgA ELISA antibody absorbances in serum and respiratory tract washings revealed no correlation with lung score. Six weeks after challenge, pigs previously vaccinated intramuscularly mostly demonstrated greater IgG and IgA responses in respiratory tract washings, and greater IgG serum antibody responses, than those vaccinated by intraperitoneal injection.
CONCLUSION: Pigs vaccinated with M hyponeumoniae antigens in the molecular size range of 70 to 85 kDa showed a significant reduction in lung lesions compared with unvaccinated control animals after experimental challenge. IgG and IgA antibody concentrations in serum and respiratory tract washings after vaccination do not provide a useful prognostic indicator of protection from enzootic pneumonia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9258425     DOI: 10.1111/j.1751-0813.1997.tb14383.x

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  25 in total

1.  Sequence TTKF ↓ QE defines the site of proteolytic cleavage in Mhp683 protein, a novel glycosaminoglycan and cilium adhesin of Mycoplasma hyopneumoniae.

Authors:  Daniel R Bogema; Nichollas E Scott; Matthew P Padula; Jessica L Tacchi; Benjamin B A Raymond; Cheryl Jenkins; Stuart J Cordwell; F Chris Minion; Mark J Walker; Steven P Djordjevic
Journal:  J Biol Chem       Date:  2011-10-03       Impact factor: 5.157

2.  Recombinant secreted antigens from Mycoplasma hyopneumoniae delivered as a cocktail vaccine enhance the immune response of mice.

Authors:  Vanessa Galli; Simone Simionatto; Silvana Beutinger Marchioro; Gustavo Henrique Ferrero Klabunde; Fabricio Rochedo Conceição; Odir Antônio Dellagostin
Journal:  Clin Vaccine Immunol       Date:  2013-06-26

3.  A processed multidomain mycoplasma hyopneumoniae adhesin binds fibronectin, plasminogen, and swine respiratory cilia.

Authors:  Lisa M Seymour; Ania T Deutscher; Cheryl Jenkins; Tracey A Kuit; Linda Falconer; F Chris Minion; Ben Crossett; Matthew Padula; Nicholas E Dixon; Steven P Djordjevic; Mark J Walker
Journal:  J Biol Chem       Date:  2010-09-02       Impact factor: 5.157

4.  Immune responses induced by replication-defective adenovirus expressing the C-terminal portion of the Mycoplasma hyopneumoniae P97 adhesin.

Authors:  F R Okamba; E Moreau; K Cheikh Saad Bouh; C A Gagnon; B Massie; M Arella
Journal:  Clin Vaccine Immunol       Date:  2007-04-04

5.  Experimental evaluation of Mycoplasma hyopneumoniae bacterin against a Korean M. hyopneumoniae challenge.

Authors:  SooHwan Kim; Taehwan Oh; Siyeon Yang; Hyejean Cho; Chanhee Chae
Journal:  Can J Vet Res       Date:  2021-01       Impact factor: 1.310

6.  Expression and immunogenicity of Mycoplasma hyopneumoniae heat shock protein antigen P42 by DNA vaccination.

Authors:  Ya-Lei Chen; Shao-Ning Wang; Wen-Jen Yang; Yi-Jiun Chen; Hsi-Hsun Lin; David Shiuan
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

7.  Vaccination of piglets up to 1 week of age with a single-dose Mycoplasma hyopneumoniae vaccine induces protective immunity within 2 weeks against virulent challenge in the presence of maternally derived antibodies.

Authors:  Stephen Wilson; Leen Van Brussel; Gillian Saunders; Paul Runnels; Lucas Taylor; Dan Fredrickson; Jeremy Salt
Journal:  Clin Vaccine Immunol       Date:  2013-03-13

8.  Comparison of 3 vaccination strategies against porcine reproductive and respiratory syndrome virus, Mycoplasma hyopneumoniae, and porcine circovirus type 2 on a 3 pathogen challenge model.

Authors:  Jiwoon Jeong; Ikjae Kang; Seeun Kim; Kee Hwan Park; Changhoon Park; Chanhee Chae
Journal:  Can J Vet Res       Date:  2018-01       Impact factor: 1.310

Review 9.  Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs.

Authors:  Dominiek Maes; Filip Boyen; Bert Devriendt; Peter Kuhnert; Artur Summerfield; Freddy Haesebrouck
Journal:  Vet Res       Date:  2021-05-08       Impact factor: 3.683

10.  Transfer of Mycoplasma hyopneumoniae-specific cell mediated immunity to neonatal piglets.

Authors:  Bert Devriendt; Dominiek Maes; Evelien Biebaut; Lisa Beuckelaere; Filip Boyen; Freddy Haesebrouck; Charles-Oliver Gomez-Duran
Journal:  Vet Res       Date:  2021-06-30       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.